Westchester Capital Management (New York)’s Frazier Lifesciences Acquisition Corporation Unit FLACU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-19,898
Closed -$199K 582
2022
Q3
$199K Sell
19,898
-64,474
-76% -$650K 0.01% 404
2022
Q2
$832K Hold
84,372
0.02% 319
2022
Q1
$831K Hold
84,372
0.02% 317
2021
Q4
$836K Sell
84,372
-9,203
-10% -$92.1K 0.02% 280
2021
Q3
$936K Hold
93,575
0.03% 231
2021
Q2
$940K Hold
93,575
0.02% 216
2021
Q1
$951K Buy
93,575
+69,631
+291% +$742K 0.03% 229
2020
Q4
$248K Buy
+23,944
New +$250K 0.01% 188

Westchester Capital Management (New York)'s FLACU Position: Q4 2022 in Review

Westchester Capital Management (New York) sold out of Frazier Lifesciences Acquisition Corporation Unit (FLACU) in Q4 2022, closing a stake of 19,898 shares — an estimated $199K sold.

Westchester Capital Management (New York) first reported a position in FLACU in Q4 2020 and held it in 8 quarters. The position peaked at $951K in Q1 2021. 0 funds tracked by Wall St. Rank hold FLACU as of Q4 2022.

  • Westchester Capital Management (New York) reported no remaining Frazier Lifesciences Acquisition Corporation Unit position as of Q4 2022 after selling out during the quarter.
  • Westchester Capital Management (New York) sold 19,898 Frazier Lifesciences Acquisition Corporation Unit shares in Q4 2022, an estimated $199K.
  • Westchester Capital Management (New York) first reported a position in Frazier Lifesciences Acquisition Corporation Unit in Q4 2020 and held it in 8 quarters.
  • Westchester Capital Management (New York)'s Frazier Lifesciences Acquisition Corporation Unit position peaked at $951K in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corporation Unit as of Q4 2022.

Based on Westchester Capital Management (New York)'s 13F filing for Q4 2022, filed 14 Feb 2023.